Summit Therapeutics Inc. (SMMT) Return on equity 2018–2024
Summit Therapeutics Inc. (SMMT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-56.9%FY2024 · since FY2018: 18.9% → -56.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -56.9% | +734.6 pp |
| FY2023 | -791.5% | -729.3 pp |
| FY2022 | -62.2% | +44.2 pp |
| FY2021 | -106.4% | -40.1 pp |
| FY2020 | -66.3% | — |
| FY2018 | 18.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice